Viewing Study NCT05766605



Ignite Creation Date: 2024-05-06 @ 6:43 PM
Last Modification Date: 2024-10-26 @ 2:53 PM
Study NCT ID: NCT05766605
Status: RECRUITING
Last Update Posted: 2023-03-13
First Post: 2023-03-01

Brief Title: Applicability of PDOX in Patients With Primary Liver Cancer A Randomized Controlled Trial
Sponsor: Zhujiang Hospital
Organization: Zhujiang Hospital

Study Overview

Official Title: Applicability of Patient Derived Orthotopic Xenograft PDOX in Patients With Primary Liver Cancer A Randomized Controlled Trial
Status: RECRUITING
Status Verified Date: 2023-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery
Detailed Description: Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization will be collected

excluding incomplete data The primary endpoint was the one-year disease-free survivalDFS rate Secondary endpoint was the adverse event

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None